Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report 2026

The veterinary active pharmaceutical ingredients manufacturing market size has grown strongly in recent years. It will grow from $8.03 billion in 2025 to $8.71 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to rising prevalence of animal diseases, growth of livestock and companion animal population, expansion of veterinary pharmaceutical industry, development of conventional chemical-based apis, increasing demand for anti-infective and antiparasitic drugs.

The veterinary active pharmaceutical ingredients manufacturing market size is expected to see strong growth in the next few years. It will grow to $12.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to adoption of biological and recombinant apis, growth in contract manufacturing services, rising demand for highly potent apis, regulatory support for veterinary pharmaceutical production, increasing focus on vaccine api innovations. Major trends in the forecast period include growth of contract manufacturing for veterinary apis, development of highly potent apis, expansion of in-house api production capabilities, increasing focus on anti-infective and antiparasitic apis, innovation in vaccine api formulations.

The rising prevalence of zoonotic diseases is expected to drive growth in the veterinary active pharmaceutical ingredients (API) manufacturing market in the coming years. Zoonotic diseases, also known as zoonoses, are infectious illnesses that can be transmitted naturally between animals and humans. The incidence of zoonotic diseases is increasing due to greater human-animal interactions, which provide more opportunities for pathogens to spread and establish new infections. Veterinary APIs are used in the development of vaccines that prevent the transmission of zoonotic diseases from animals to humans. Additionally, the use of veterinary APIs helps combat antibiotic resistance, a significant concern in treating zoonotic infections. For example, in February 2023, according to the Council on Foreign Relations (CFR), a US-based independent, nonpartisan think tank and publisher, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases had zoonotic origins. Globally, zoonoses cause 2.7 million human deaths and 2.5 billion disease episodes in people each year. Therefore, the increasing prevalence of zoonotic diseases is driving the veterinary API manufacturing market.

Leading players in the veterinary API manufacturing market are focusing on establishing manufacturing facilities to gain a competitive edge. These plants produce active pharmaceutical ingredients used in the formulation of veterinary drugs. For instance, in October 2023, Stallen South Asia Private Limited, an India-based animal health company, inaugurated a new veterinary API facility for Halquinol, a non-antibiotic growth promoter belonging to the hydroxyquinoline group. The facility produces a combination of 5-chloro-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, and 7-chloro-8-hydroxyquinoline. Products include Halquinol 98%, manufactured according to British Pharmacopeia 1980 (BP 80) standards. In addition to the more common 60% and 12% formulations, Stallen is able to supply 98% as a chemical API for veterinary formulations and feed additives. The company aims to reduce reliance on imports from China by gradually introducing a broad range of APIs from this plant to support the animal health industry.

In May 2024, Veterinary Pharmacy Corporation, a US-based provider of veterinary pharmacy products and animal health services, acquired Diamond Animal Health Inc. for an undisclosed amount. Through this acquisition, Veterinary Pharmacy Corporation expanded its contract manufacturing and pharmaceutical development capabilities in the animal health sector, enhancing its manufacturing footprint and broadening its portfolio of active pharmaceutical ingredients and biologics for veterinary applications. Diamond Animal Health Inc. is a US-based provider of contract manufacturing, research and development, and regulatory services for animal pharmaceuticals and vaccines, supporting API production and formulation for both livestock and companion animals.

Major companies operating in the veterinary active pharmaceutical ingredients manufacturing market are Alivira Animal Health Limited, Excel Industries Limited, Ofichem Group B.V., Jiangsu Lingyun Pharmaceutical Co. Ltd., SUANFARMA S.A., NGL Fine-Chem Limited, FIS - Fabbrica Italiana Sintetici S.p.A., Lupin Limited, Aurobindo Pharma Limited, Saneca Pharmaceuticals AS, Neuland Laboratories Limited, Divi's Laboratories Limited, Zoetis Inc., Grupo Indukern S.L., Sequent Scientific Limited, Chempro Pharma Private Limited, AMGIS Lifescience Ltd., Huvepharma AD, Vetpharma Animal Health S.L., Qilu Pharma Spain S.A., INDUKERN Chemie AG, Chemopharma S.A., Norbrook Laboratories Limited, Ceva Santé Animale S.A., Vetoquinol S.A., Virbac S.A.

North America was the largest region in the veterinary active pharmaceutical ingredients manufacturing market in 2025. The regions covered in the veterinary active pharmaceutical ingredients manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary active pharmaceutical ingredients manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the veterinary active pharmaceutical ingredients manufacturing market by increasing the cost of imported raw materials, chemical intermediates, and biological components, disrupting supply chains for chemical, biological, and highly potent APIs. Regions such as North America and Europe, which rely heavily on imports for advanced API production, are most affected, particularly in anti-infective and vaccine API segments. On the positive side, tariffs promote local API manufacturing, encourage investment in domestic production facilities, and support development of cost-efficient veterinary medicines.

The veterinary active pharmaceutical ingredients manufacturing market research report is one of a series of new reports that provides veterinary active pharmaceutical ingredients manufacturing market statistics, including veterinary active pharmaceutical ingredients manufacturing industry global market size, regional shares, competitors with a veterinary active pharmaceutical ingredients manufacturing market share, detailed veterinary active pharmaceutical ingredients manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary active pharmaceutical ingredients manufacturing industry. This veterinary active pharmaceutical ingredients manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary Active Pharmaceutical Ingredients (APIs) manufacturing involves the production of chemical compounds that are biologically active and utilized in the formulation of veterinary medicines. These APIs play a crucial role in treating diseases and maintaining health in animals, including both livestock and pets. The manufacturing process is designed to ensure the quality, safety, and efficacy of the medications that enhance animal welfare and health outcomes.

The primary products within veterinary active pharmaceutical ingredients manufacturing encompass anti-infectives, vaccines, and NSAIDs. Active Pharmaceutical Ingredients (APIs) are the core elements of pharmaceutical medications that exert specific effects on the body, aiding in the treatment of diseases. Service types associated with this field include in-house production and contract outsourcing. Additionally, synthetic types of APIs comprise chemical-based APIs, biological APIs, and highly potent APIs. These categories delineate the diverse methodologies involved in producing these vital components for veterinary pharmaceuticals.

The veterinary active pharmaceutical ingredients manufacturing market consists of revenues earned by entities by biologics and bulk drugs that are used to create components in medications which are responsible for the positive veterinary health impacts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.